
the simpler. the better. I mostly tweet about $AFMD
Joined October 2018
- Tweets717
- Following0
- Followers169
- Likes466
🧬 777 retweeted
Replying to @graham74GC
🧬 777 retweeted
Confirmed delay for those 5 pts which will be reported on Q3 $AFMD
Replying to @8thKingofRome @JacobPlieth
Another user @Biotech777 already posted it. They explained it very well.
🧬 777 retweeted
🚨Reminder AACR Regular Abstract Titles and Texts Posted to Online Itinerary Planner (4:30 p.m. ET)
See companies who have already announced presentations on the Conference Calendar: biopharmcatalyst.com/calenda…
Get company press releases straight to your browser or email here: biopharmcatalyst.com/account…
🧬 777 retweeted
#ASH23
Abstract 774 - Yago Nieto et al. @lab_rezvani
CB-derived CIML ex vivo expanded NK cells precomplexed with the bispecific AFM13 construct shows high response rates in pts with CD30+ lymphoma, double refractory to brentuximab vedotin and checkpoint inhibitors.
Promising!
🧬 777 retweeted
For patients with refractory CD30+ lymphomas, a promising new therapy: cord blood-derived NK cells that were preactivated and expanded then complexed with the innate cell engager AFM13. Data presented at #ASH23 by our Dr. Yago Nieto. Read more: bit.ly/46KHxgi #EndCancer – at San Diego, CA
🧬 777 retweeted
Replying to @BrianUherek
Just finished voting; voted against the whole board and against reverse split too. Urge every investor in $AFMD to vote, and consider that current management treats the company as their own personal science experiment, and the shareholders as their unlimited piggybank.
🧬 777 retweeted
Long overdue. At least it's a sign that mgmt...finally, finally...understands that they have mismanaged and miscalculated. $AFMD
Replying to @RNA_Biotech
$AFMD reduces headcount by 25%
"In April 2023, Affimed conducted a reorganization of its operations to focus on its three clinical programs. As a result, the Company reduced its full-time equivalent headcount by approximately 25 percent."
🧬 777 retweeted
Hello BioTwitter.
Please support with likes my LinkedIn post, where i'm asking tough questions to $AFMD team and its CEO - Adi Hoess specifically, As investors we need to be active to save our money!
linkedin.com/in/nikolai-briu…
🧬 777 retweeted
Replying to @Biotech777
🧬 777 retweeted
$FATE iPSC + anti-pdl1 mAb data to be released at SITC. If no responses, further validation of $AFMD approach with ICEs becoming “The keytruda of NKCEs”.
Replying to @RNAiAnalyst
BIGGER
repeat
* let others build (CAR-)NK cell capabilities of all kind & partner their cells with own or partnered targets
* let others execute trials & take risks
* cash in upfront, milestones & royalties
until
$AFMD is the Keytruda 4 NK-cell industry everybody needs & wants
🧬 777 retweeted
$AFMD innate cell engagers at #SITC22 should be interesting for @affimed’s own/partnered molecules and for combinations development
(but again we need stronger management).
Ps. Artiva’s AB101 data will be relevant for Affimed (t/t @dhovekamp42) not sure it will FATE data
🧬 777 retweeted
Replying to @genentech
Very interesting. Look at the more effective and safer NK cell engagers + NK cells developed by your partner #Affimed. The MoA of the NKCEs at the microscopy looks quite interesting (and powerful).
Curious to see your new partnered NKCE(s)!
Paper:
science.org/content/article/…
🧬 777 retweeted
NK Cells Complexed with CD30/CD16A Bispecific Antibody Offers Potential Treatment for R/R Lymphoma oncologydirectory.com/news/n…
🧬 777 retweeted
There is nothing more amazing in one’s career than having a preclinical concept translated to the clinic. Congratulations @lucila_kerbauy, everyone in the lab, the MDACC cord bank and GMP, and especially Dr Nieto and the clinical team. @ScienceMagazine @MDAndersonNews #AACR2022 – at Houston, TX
Super potent NK cells loaded with AFM13 dramatically kill HL cancer cells. Check out this article in @ScienceMagazine about the data presented at #AACR22 by Dr. Rezvani and Dr. Nieto! @lab_rezvani @MDAndersonNews #NK #AFM13 #AbNKcomplex science.org/content/article/…
🧬 777 retweeted
Cantor Fitzgerald reiterates $AFMD Overweight/$12PT~stock remains one of firm's top ideas for '22, believes the updated data of AFM13 + NK combo lend strong support to their best-case scenario
🧬 777 retweeted
Lymphoma patients are not always responsive to current therapy options. Affimed’s mission to revolutionize the treatment landscape starts with AFM13, a novel approach of activating the #InnateImmunity against cancer: https://nitter.cf/t.co/gqdRxBVFKT
#InnatelyAffimed #AFM13









































